|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
serotonin reuptake inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Desyrel
gptkb:Oleptro
gptkb:Trazodone_hydrochloride
gptkb:Trazorel
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
MAO inhibitors
hypersensitivity
|
|
gptkbp:discontinued
|
severe liver disease
angle-closure glaucoma
prolonged QT interval
recent heart attack
|
|
gptkbp:dosage_form
|
150 to 400 mg per day
50 to 100 mg for sleep
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trazodone
|
|
gptkbp:ingredients
|
C19 H22 Cl N5 O
|
|
gptkbp:interacts_with
|
gptkb:beer
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
N06 A X05
|
|
gptkbp:is_available_on
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:is_used_for
|
gptkb:historical_event
anxiety
insomnia
|
|
gptkbp:lifespan
|
5 to 9 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:premiered_on
|
1 to 2 weeks
|
|
gptkbp:side_effect
|
dizziness
nausea
drowsiness
dry mouth
blurred vision
|
|
gptkbp:symptoms
|
headache
nausea
irritability
insomnia
|
|
gptkbp:type_of
|
379-26-2
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|